New regulators and activators of the STING immune pathway

Novel regulatory mechanisms and agonists of STING

NIH-funded research Ut Southwestern Medical Center · NIH-11285178

This work is developing new molecules to switch on the STING immune pathway to help the immune system fight cancer and viral infections.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionUt Southwestern Medical Center NIH-funded
Lab location1 site (Dallas, United States)
Project IDNIH-11285178 on NIH RePORTER

What this research studies

From my perspective, researchers are figuring out how the STING immune switch is controlled and are designing compounds that can activate it. They will run lab experiments in cells and use animal models to see how these activators trigger interferon and other immune responses. The team will also look at whether turning on STING can make cancer immunotherapies like PD‑1 blockers work better. These are preclinical lab and animal tests, not treatments you would receive yet, but they aim to guide future clinical trials.

Who could benefit from this research

Good fit: Patients with cancer—particularly those eligible for or receiving immune checkpoint therapy—would be the most likely candidates for future trials based on this research.

Not a fit: People with non-cancer conditions or patients who need immediate standard treatment are unlikely to get direct benefit from this preclinical research.

Why it matters

Potential benefit: If successful, this work could lead to new drugs that boost anti-tumor and anti-viral immunity and improve responses to existing immunotherapies.

How similar studies have performed: Related laboratory and animal studies have shown promise and several STING agonists have entered early clinical trials, though clinical results have been mixed so far.

Where this research is happening

Dallas, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Anti-Cancer Agents
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.